Skip to main content
SpringerLink
Log in

Site-Specific Immunosuppression with Topical Agents

  • Chapter
Local Immunosuppression of Organ Transplants

Part of the book series: Medical Intelligence Unit ((MIU.LANDES))

  • 55 Accesses

Abstract

Novel immunosuppressive compounds derived from fungi have unique properties compared to conventional immunosuppressants: they are selective in their mechanism of action, and are potent anti-inflammatory compounds. Cyclosporin (CsA), FK506 and rapamycin (Fig. 14.1) derivatives are well recognized for their powerful ability to permanently alter immune responsiveness, in comparison to conventional agents, so that some degree of selective immunologic nonreactivity can be achieved. Therefore, it would be extremely advantageous to develop topical formulations of novel immunosuppressants for localized site-specific action.1

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gruber SA. The case for local immunosuppression. Transplantation 1992; 54 (1): 1.

    Article  PubMed  CAS  Google Scholar 

  2. Black KS, Hewitt CW, Chau CLC et al. Transdermal application of cyclosporine prolongs skin allograft survival. Transplant Proc 1988; 20 (2 Suppl 2): 660.

    PubMed  CAS  Google Scholar 

  3. Black KS, Nguyen DK, Proctor CM et al. Site-specific suppression of cell-mediated immunity by cyclosporine. J Invest Dermatol 1990; 94 (5): 644.

    Article  PubMed  CAS  Google Scholar 

  4. Black KS, Patel MP, Patel AP et al. Mechanisms of site-specific immunosuppression. Transplant Proc 1991; 23 (1): 120.

    PubMed  CAS  Google Scholar 

  5. Tatem L, Hou A, Black KS et al. Digital image analysis of major histocompatibility complex class I and class II expression during site-specific immune suppression with topical cyclosporine. Transplant Proc 1995; 27 (1): 344.

    PubMed  CAS  Google Scholar 

  6. Llull R, Lee TP, Vu AN et al. Site-specific immune suppression with topical cyclosporine. Synergism with combined topical corticosteroid added during the maintenance phase. Transplantation 1995; 59: 1483.

    Article  PubMed  CAS  Google Scholar 

  7. Achauer BM, Hewitt CW, Black KS et al. Long-term skin allograft survival after short-term cyclosporine treatment in a patient with massive burns. Lancet 1986; 1: 14.

    Article  PubMed  CAS  Google Scholar 

  8. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555.

    PubMed  CAS  Google Scholar 

  9. Thomson AW, Moon DK, Inoue Y et al. Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporine A-treated guinea-pigs. Immunology 1983; 48: 301.

    PubMed  CAS  Google Scholar 

  10. Harper JI, Keat ACS, Staughton RCD. Cyclosporin for psoriasis. Lancet 1984; 2: 981.

    Article  PubMed  CAS  Google Scholar 

  11. Thivolet J, Barthelemy H, Rigot-Muller G et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; 1: 334.

    Article  PubMed  CAS  Google Scholar 

  12. van Hooff JP, Leunissem KM, v.d. Staak W. Cyclosporin and psoriasis. Lancet 1985; 1: 335.

    Article  PubMed  Google Scholar 

  13. Velthuis PJ, Jesserun RF. Improvement of ichthyosis by cyclosporin. Lancet 1985; 1: 335.

    Article  PubMed  CAS  Google Scholar 

  14. Borel JF. Cyclosporine: historical perspectives. Transplant Proc 1983; 15 (4): 2219.

    Google Scholar 

  15. Hess AD, Esa AH, Colombani PM. Mechanisms of action of cyclosporine: effect on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 1988; 20 (2): 29.

    PubMed  CAS  Google Scholar 

  16. Valdimarsson H, Baker BS, Jonsdottir I et al. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986; 7 (9): 256.

    Article  Google Scholar 

  17. Aldridge RD, Simpson JG, Whiting PH et al. Cyclosporin and skin disease. Lancet 1985; 1: 160.

    Article  PubMed  CAS  Google Scholar 

  18. Billingham RE, Krohn PL, Medawar PB. Effect of locally applied cortisone acetate on survival of skin homografts in rabbits. Br Med J 1951; 2: 1049.

    Article  PubMed  CAS  Google Scholar 

  19. Boss P, Jolley W, Ainsworth E. Mechanisms of action of topically applied triamcinolone acetonide in prolonging skin allograft survival time. Transplantation 1973; 15: 17.

    Article  PubMed  CAS  Google Scholar 

  20. Lai CS, Wesseler TA, Alexander W et al. Long-term survival of skin allografts in rats treated with topical cyclosporine. Transplantation 1987; 44 (1): 83.

    Article  PubMed  CAS  Google Scholar 

  21. Zhao XF, Schroeder TJ, Alexander JW et al. The prolongation of skin allograft survival by topical use of cyclosporine A. Transplant Proc 1988; 20 (2 Suppl 2): 670.

    PubMed  CAS  Google Scholar 

  22. Zhao XF, Alexander JW, Schroeder T et al. The synergistic effect of low-dose cyclosporine and fluocinolone acetonide on the survival of rat allogeneic skin grafts. Transplantation 1988; 46: 490.

    Article  PubMed  CAS  Google Scholar 

  23. Aldridge RD, Thomson AW, Rankin R et al. Inhibition of contact sensitivity reactions to DNFB by topical cyclosporin application in the guinea-pig. Clin Exp Immunol 1985; 59 (1): 23.

    PubMed  CAS  Google Scholar 

  24. De Prost Y, Teillac D, Paquez F et al. Placebo-controlled trial of topical cyclosporin in severe alopecia areata. Lancet 1986; 2: 803.

    Article  PubMed  Google Scholar 

  25. Parodi A, Rebora A. Topical cyclosporine in alopecia areata. Arch Dermatol 1987; 123 (2): 165.

    Article  PubMed  CAS  Google Scholar 

  26. Thompson AW, Aldridge RD, Sewell HF. Topical cyclosporin in alopecia areata and nickel contact dermatitis. Lancet 1986; 2: 971.

    Article  PubMed  CAS  Google Scholar 

  27. Aldridge RD, Sewell HF, King G et al. Topical cyclosporin A in nickel contact hypersensitivity: results of a preliminary clinical and immunohistochemical investi- gation. Clin Exp Immunol 1986; 66 (3): 582.

    PubMed  CAS  Google Scholar 

  28. Griffiths CE, Powles AV, Baker BS et al. Topical cyclosporine and psoriasis. Lancet 1987; 1: 806.

    Article  PubMed  CAS  Google Scholar 

  29. Thomson AW, Sewell HF, Aldridge RD. Topical cyclosporin and immunologically-mediated skin disorders. Lancet 1987; 1: 1212.

    Article  PubMed  CAS  Google Scholar 

  30. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992; 98 (6): 851.

    Article  PubMed  CAS  Google Scholar 

  31. Foets B, Missotten L, Vanderveeren P et al. Prolonged survival of allogeneic corneal grafts in rabbits treated with topically applied cyclosporin A: systemic absorption and local immunosuppressive effect. Br J Ophthalmol 1985; 69 (8): 600.

    Article  PubMed  CAS  Google Scholar 

  32. Behrens-Baumann W, Theuring S, Brewitt H. The effect of topical cyclosporin A on the rabbit cornea. A clinical and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 1986; 224 (6): 520.

    Article  PubMed  CAS  Google Scholar 

  33. Williams KA, Erickson SA, Coster DJ. Topical steroid, cyclosporin A, and the outcome of rat corneal allografts. Br J Ophthalmol 1987; 71 (3): 239.

    Article  PubMed  CAS  Google Scholar 

  34. Duncan JI, Payne SN, Winfield AJ et al. Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity. Br J of Dermatol 1990; 123 (5): 631.

    Article  CAS  Google Scholar 

  35. Duncan JI, Wakeel RA, Winfield AJ et al. Immunomodulation of psoriasis with a topical cyclosporine A formulation. Acta Dermato-Venereologica 1993; 73 (2): 84.

    PubMed  CAS  Google Scholar 

  36. Surber C, Itin P, Muchner S et al. Effects of new topical cyclosporin formulation on human allergic contact dermatitis. Contact Dermatitis 1992; 26 (2): 116.

    Article  PubMed  CAS  Google Scholar 

  37. Eisen D, Ellis CN, Duell EA et al. Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis. N Engl J Med 1990; 323 (5): 290.

    Article  PubMed  CAS  Google Scholar 

  38. Epstein JB, Reece DE. Topical cyclosporine A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplantation 1994; 13 (1): 81.

    PubMed  CAS  Google Scholar 

  39. Ho VC, Griffiths CE, Ellis CN et al. Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study. J Am Acad Dermatol 1990; 22 (1): 94

    Article  PubMed  CAS  Google Scholar 

  40. Sonmez YE, Ercan E, Savci N et al. Longterm survival of skin allograft in rats by topical use of cyclosporine A. Turk J Med Biol Res 1991; 2 (2): 143.

    Google Scholar 

  41. Bierer BE. Cyclosporin A, FK506, and rapamycin: Binding to immunophilins and biological action. Chem Immunol 1994; 59:128.

    Google Scholar 

  42. Schleuning M, Duggan A, Reem GH. Cyclosporine does not inhibit the early transducing signals generated by the activation of human thymocytes. Transplant Proc 1988; 20 (2): 63.

    PubMed  CAS  Google Scholar 

  43. Hewitt CW, Black KS, Gonzalez GA et al. Decreased reactivity of allosera against target lymphocytes obtained following thermal injury or long-term cyclosporine treatment. Clin Immunol Immunopathol 1987; 45: 395.

    Article  PubMed  CAS  Google Scholar 

  44. Wilkinson PC, Higgins A. Cyclosporin A inhibits mitogen-activated but not phorbol ester-activated locomotion of human lymphocytes. Immunology 1987; 61: 311.

    PubMed  CAS  Google Scholar 

  45. Hopt UT, Erath F, Schareck W et al. Effect of cyclosporin A on local inflammation in rejecting allografts. Transplant Proc 1988; 20 (2): 163.

    PubMed  CAS  Google Scholar 

  46. Norin AJ, Kamholz SL, Pinsker KL et al. Concavalin A-dependent cell-mediated cytotoxicity in bronchoaleolar lavage fluid. Transplantation 1986; 42 (5): 466.

    Article  PubMed  CAS  Google Scholar 

  47. Hanto DW, Ulrich HT, Hoffman R et al. Recruitment of unsensitized circulating lymphocytes to sites of allogeneic cellular interactions. Transplantation 1982; 33 (5): 541.

    Article  PubMed  CAS  Google Scholar 

  48. Mayer TG, Bhan AK, Winn HJ. Immuno histochemical analysis of skin graft rejecmatol 1990; 22 (1): 94.

    Google Scholar 

  49. Orosz CG, Zinn NE, Sirinek L et al. In vivo mechanisms of alloreactivity 1. Frequency of donor-reactive cytotoxic T lymphocytes in sponge matrix allografts. Transplantation 1986; 41: 75.

    Article  PubMed  CAS  Google Scholar 

  50. Orosz CG, Zinn NE, Sirinek LP et al. In vivo mechanisms of alloreactivity. II. Allospecificity of cytotoxic T lymphocytes in sponge matrix allografts as determined by limiting dilution analysis. Transplantation 1986; 41 (1): 84.

    Article  PubMed  CAS  Google Scholar 

  51. Havele C, Paetkau V. Cyclosporine blocks the activation of antigen dependent cytotoxic T lymphocytes directly by an IL-2 independent mechanism. J Immunol 1988; 140 (10): 3303.

    PubMed  CAS  Google Scholar 

  52. Mellert J, Hopt UT, Erath F et al. Differential effects of azathioprine (Aza), cyclosporine A (CsA) and dexamethaxone (Dexa) on lymphokine mediated inflammation in rejecting allografts. Transplant Proc 1989; 21: 98.

    PubMed  CAS  Google Scholar 

  53. Erjefalt I, Greiff L, Alkner U et al. Allergen-induced biphasic plasma exudation responses in guinea pig large airways. Am Rev Respir Dis 1993; 148 (3): 695.

    Article  PubMed  CAS  Google Scholar 

  54. Holgate ST, Djukanovic R, Wilson J et al. Allergic inflammation and its pharmacological modulation in asthma. Int Arch Allergy Appl Immunol 1991; 94: 210.

    Article  PubMed  CAS  Google Scholar 

  55. Bierer BE. Immunosuppressive agents targeting T-cell activation pathways. In: Przepiorka D, Sollinger H, eds. Recent Developments in Transplantation Medicine. Physicians & Scientists Publishing Co., Inc. 1994: 9.

    Google Scholar 

Download references

Authors
  1. Kirby S. Black
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles W. Hewitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Black, K.S., Hewitt, C.W. (1996). Site-Specific Immunosuppression with Topical Agents. In: Local Immunosuppression of Organ Transplants. Medical Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22105-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-22105-1_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-22107-5

  • Online ISBN: 978-3-662-22105-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation